Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis

Sousa-Pinto B, Vieira RJ, Bognanni A, et al.  Allergy. 2025; 80: 94-105. doi:10.1111/all.16384

Abstract

Background

Intranasal antihistamines (INAH), corticosteroids (INCS), and their fixed combinations (INAH+INCS) are one of the cornerstones of the treatment of allergic rhinitis (AR). We performed a systematic review and network-meta-analysis comparing the efficacy and safety of INAH, INCS, and INAH+INCS in patients with AR.

Methods

We searched four electronic bibliographic databases and three clinical trial databases for randomised controlled trials assessing the use of INAH, INCS, and INAH+INCS in adults with seasonal or perennial AR. We performed a network meta-analysis on the Total Nasal Symptom Score, Total Ocular Symptom Score, Rhinoconjunctivitis Quality-of-Life Questionnaire, development of adverse events, and withdrawals due to adverse events.

Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers

Bousquet, J., Klimek, L., Liu, M., Nguyen, D.T., Ramalingam, R.K., Canonica, G.W. and Berger, W.E. (2025), Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.1498

Abstract

The primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.10% AZE. This study was performed in healthy volunteers based on the pharmacokinetic parameters maximum plasma concentration and area under the plasma concentration–time curve from time zero to the last measurable concentration. This was a Phase 1, open-label, single-center, randomized, parallel-group study.

Mean azelastine plasma concentration with time.

Subjects were randomized to 1 of 3 treatment groups: (1) 0.10% AZE (treatment A), (2) 0.15% AZE (treatment B) (Groups 1 and 2 both containing sorbitol and sucralose), and (3) the commercially available 0.10% AZE (treatment C). A total of 54 subjects were randomized and received treatment A, B, or C.

The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases

Zhang H, Cao Y, Jiang H, Zhou Q, Yang Q, Cheng L. Clin Transl Allergy. 2025;e70020. https://doi.org/10.1002/clt2.70020

Abstract

Background

Digital health, digital medicine, and digital therapeutics integrate advanced computer technologies into healthcare, aiming to improve efficiency and patient outcomes. These technologies offer innovative solutions for the management of allergic diseases, which affect a significant proportion of the global population and are increasing in prevalence.

Application scenarios of digital health in allergy for both physicians and patients.

Body

This review examines the current progress and future potential of digital health in allergic disease management. It highlights key advancements, including telehealth, mobile health (mHealth), artificial intelligence, clinical decision support systems (CDSS), and digital biomarkers, with a focus on their relevance to allergic disease management.

Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction

Mallick, R., Hahn, N. & Scalchunes, C. Allergy Asthma Clin Immunol 21, 2 (2025). https://doi.org/10.1186/s13223-024-00939-y

Abstract

Background

Immunoglobulin replacement therapy (IgRT) is the current standard of care for primary antibody deficiency patients (majority of all primary immunodeficiency (PID) diseases), with growing real-world evidence supporting use for secondary immunodeficiency (SID) patients. Infusion methods and practices can affect patients’ satisfaction with their treatment and perception of their health-related quality of life.

Methods

An online survey of US patients with PID and SID was conducted. This research investigates primarily the impact of two IgRT infusion methods, intravenous immunoglobulin therapy (IVIG) and subcutaneous immunoglobulin (SCIG), on the patient reported outcome (PRO) Life Quality Index (LQI) tool.

Allergic Rhinitis: Impact on Quality of Life

Nuhi A, Jintu A, Amresh K, Harinderjit S. Ann Pulm Res Med. 2024; 2(1): 1007.

Abstract

Besides its usual symptoms, allergic rhinitis has a substantial negative influence on one's physical and emotional well-being as well as social and mental interactions and overall Quality of Life (QOL). Environmental causes and changes in lifestyle are contributing to its rising global incidence. Nasal congestion symptoms can make it difficult to sleep, wear you out, and interfere with everyday activities, especially when they coexist with other disorders like asthma. Studies have demonstrated the efficacy of medication and variations in prevalence according to gender. This research attempts to assess the effects of allergic rhinitis on quality of life in detail. Pharmacotherapy and avoiding allergens are the best forms of treatment. When appropriate, targeted symptom control with immunotherapy and an assessment for allergic rhinitis should be taken into account.

Cost-of-illness analysis of chronic urticaria clinical management in five countries of Latin America

Sánchez J, Álvarez L, Larco JI, et al. Clin Transl Allergy. 2025;e70016. https://doi.org/10.1002/clt2.70016

Abstract

Introduction

Chronic spontaneous urticaria (CSU) is a disease with a high impact on the quality of life of patients. There are some evaluations of the economic cost of the disease in developed countries, but there is little information about the economic cost of the disease in developing countries. Our aim was to assess the economic diagnostic and therapeutic expenses of CSU in five Latin American (LA) countries.

Methods

A noninterventional multicenter cross-sectional study was conducted in five LA countries: Brazil, Colombia, Ecuador, Mexico, and Peru.

Histopathological, Cytological and Radiological Correlations in Allergy and Public Health Concerns: A Comprehensive Review

Oboma YI, Ekpenyong BO, Umar MS, Nja GME, Chelimo JJ, Igwe MC, Bunu UO. J Asthma Allergy. 2024;17:1333-1354

Abstract: Allergies represent a significant and growing public health concern, affecting millions worldwide and burdening healthcare systems substantially. Accurate diagnosis and understanding of allergy is crucial for effective management and treatment. This review aims to explore the historical evolution, current advances, and prospects of histopathological and cytological techniques in allergy diagnosis, highlighting their crucial role in modern medicine. Major biomedical, public health, and imaging databases such as PubMed, Scopus, Web of Science, and EMBASE were used. The search strategy used include specific keywords and Medical Subject Headings (MeSH) terms related to histopathology, cytology, radiology, allergic diseases, and public health. Histopathological and cytological studies play a pivotal role in elucidating the underlying mechanisms of allergies, offering insights into the cellular and tissue-level changes associated with allergic responses.

Perceptions of the impact of individual allergic rhinitis symptoms: A survey of ARIA clinical experts.

Gil-Mata S, Teixeira T, Bedbrook A, Bousquet J, Sousa-Pinto B, Vieira RJ; ARIA group.  World Allergy Organ J. 2024 Dec 3;17(12):100999. doi: 10.1016/j.waojou.2024.100999. 

Abstract

Background: Allergic rhinitis (AR) is a highly prevalent disease. We aimed to assess the symptoms that physicians who see patients with AR perceive as the most bothersome in their patients.

Methods: We performed a cross-sectional study based on an online questionnaire sent to all members of the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative. The survey included questions on the physicians' perceptions of patients' AR symptoms as well as of their own AR symptoms.

Most frequent (A) and most bothersome (B and C) allergic rhinitis symptoms
perceived in patients by ARIA members and reported by ARIA members.

Results: Among 401 respondents, 155 (38.7%) reported having AR. ARIA members reported nasal symptoms to be the most frequent (89.7%) and bothersome (80.0%) symptoms experienced by themselves.